show that that the protein produced by Drosophila version of the neurofibromatosis-1 (Nf1) gene controls the circadian machinery via the Ras/MAPK signaling pathway.Williams et al. studied Drosophila ...

In NF1, many of these medications work by blocking a specific cell signaling pathway called Ras/MAPK that is hyperactive in cells that have lost NF1 function due to gene mutation. When this signaling ...

PM CDT at the ASCO Annual MeetingMIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ...

It is known that the gene product of NF1, neurofibromin, functions as a regulator of a protein called RAS. RAS is a key component of the RAS/MAPK cell signaling pathway that controls cell growth and ...

The nuclear factor (NF)-κB, inhibitor of NF-κB (IκB) and IκB kinase (IKK) pathway is activated in response to various stimuli in many cell types. NF-κB is activated by many mechanisms ...

Pasithea Therapeutics Corp. has announced the acceptance of an abstract for a poster presentation at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 ...

for the treatment of neurofibromatosis type 1 (NF1) and other MAPK pathway driven indications, today announced the acceptance of an abstract for a poster prenstation at the Annual Meeting of the ...